13,790 Shares in Cencora, Inc. $COR Acquired by Clare Market Investments LLC

Clare Market Investments LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 13,790 shares of the company’s stock, valued at approximately $4,332,000. Cencora makes up about 0.9% of Clare Market Investments LLC’s holdings, making the stock its 19th biggest position.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. Kemnay Advisory Services Inc. purchased a new position in shares of Cencora in the fourth quarter worth $25,000. Oakworth Capital Inc. purchased a new position in Cencora during the fourth quarter valued at $26,000. Elyxium Wealth LLC purchased a new stake in shares of Cencora in the fourth quarter worth about $27,000. Archer Investment Corp raised its holdings in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC purchased a new stake in Cencora during the fourth quarter valued at $29,000. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the purchase, the director directly owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.38% of the company’s stock.

Cencora Trading Up 2.2%

NYSE:COR opened at $305.08 on Tuesday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The stock has a market capitalization of $59.36 billion, a price-to-earnings ratio of 23.38, a PEG ratio of 1.65 and a beta of 0.58. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The firm has a 50 day moving average of $277.66 and a 200 day moving average of $319.86.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter last year, the firm earned $4.42 earnings per share. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its Board of Directors has initiated a stock buyback plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is presently 18.40%.

Analyst Ratings Changes

COR has been the subject of a number of recent research reports. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Bank of America raised their price objective on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. UBS Group upped their price target on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Wells Fargo & Company cut their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Finally, Robert W. Baird lowered their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.